Who We Are

With a keen eye for innovative new products, technologies and unexploited market niches, Jeremy Delk established early success as an entrepreneur. After gaining years of experience and knowledge from working in the financial sector with Fidelity Investments, Mr. Delk was able to utilize the business acumen he learned to create Delk Enterprises in 2002. Originally a real estate development firm, Delk Enterprises has grown into a diversified investment firm with a continually expanding portfolio and a strong team of professionals. Today, Delk Enterprises owns and manages multiple businesses around the world.

We believe that small businesses are the life blood of this country and believe it is our duty to invest strategically in them, so together we can change the world.

Click to watch the video
We Believe

Investment Committee

Jeremy Delk


Mr. Delk has been a successful entrepreneur for over a decade, with a keen eye for innovative new products, technologies and unexploited market niches. Mr. Delk utilized the financial acumen he learned in the financial sector with Fidelity Investments, while working in both Boston and NYC, to incorporate Delk Enterprises in 2002. With the growth of Delk Enterprises, Mr. Delk made the decision to move back to his native Kentucky focusing on the growth of his company.

Over time, Mr. Delk expanded Delk Enterprises from primarily a real estate holdings firm to a diversified private equity portfolio including equity holdings in animal health, sports medicine, human health care, pharmacy & creating access to future IP through strategic investments in technology and human health R&D initiatives.  Today positively disrupting healthcare through portfolio companies and other strategic investments is where his primary focus lies.

Mark Linford


Mr. Linford has a diverse business background stretching over 34 years, and has always been at the forefront of new technologies. A previous business owner in industries as diverse as plastic fabrication and sanitation chemicals, one of his major achievements was the launch of a leading topical pain relief product into the Pharmacy and Medical field. Launching The Elmore Oil Company in September 2004, the product by the same name, Elmore Oil, became Australias fastest growing topical pain relief product in 2007, jumping from 18th to 5th place in its category. By 2012 Elmore Oil was positioned 4th overall in its category, and the Number 1 natural topical pain reliever in Australia, with exports to 12 countries. This brand was licensed out in 2013.

In 2006, during the ongoing development of the Elmore Oil Company, he created the Future Champions Program – a scholarship program to assist aspiring young athletes in their quest to reach their ultimate dreams. The Elmore Oil Company partnered with Australia’s Premier Educational based Charity Organisation, The Smith Family, to bring the Future Champions Program to fruition.

In 2009, furthering his philanthropic interests, Mr Linford then developed the Elmore Trust Fund for Street Children in the Philippines, to assist children from impoverished backgrounds at the grass roots level. This program, later renamed The Future Kids Program, still operates today and staff deliver food parcels to thousands of families across the Philippines on a regular basis.

Mr. Linford is currently also a shareholder and board member of Pain Away LLC, a US based distributor of pain relief and skin care products to the pharmacy and sports market in the USA. He is the CEO of Regenex Laboratories, a global supplements manufacturer and a strategic advisor to Enhanced Shockwave Solutions, Australia’s No 1 distributor of Shockwave and Acoustic Wave medical therapy equipment.

He is a former published author, writing for business and marketing magazines, a mentor for the Australian Business Development Centre and a former board member of the CVBN, Central Victoria’s premier business network. In 2016 Mr. Linford was made a Fellow of the Australian Institute of Management (FAIM), which recognises his outstanding management skills.

Nima Alavi


Nima Alavi is the pharmacist proprietor of several compounding facilities located in the heart of Melbourne, Australia, and Dubai, UAE. After working in community pharmacy for nearly a decade, Nima’s motivation in establishing tailor made compounding facilities stemmed from the need for a proactive and holistic approach in healthcare. Nima’s passion for tailored ‘compound’ pharmaceuticals was borne from the desire to help his patients achieve maximum health and not subscribe to a ‘one size fits all’ mentality. Where off the shelf medications where not optimal, Nima set about creating his own range of products and in turn offering prescribing physicians the chance to do the same. This service aims to individualize the care of each patient in order to optimize the health outcomes in a preventative manner. Since this time Nima has been dedicated to the research and development of a wide variety of compounded pharmaceuticals, working closely with other healthcare practitioners. His areas of interest include Bio-Identical Hormone Therapy, Veterinary (Equine) Compounding Cosmeceuticals, Tailored Amino Acids, Peptides, Sterile Compounding and clinical trial research. Given Nima’s global reach via his compounding pharmacy operations, he has successfully pioneered the use of peptides in practice and continues to support medical practitioners with access to current and future peptide advancements.

Don Cohen, PhD

Scientific Advisor

Professor Cohen holds a Bachelor of Science in Biological Sciences from the University of Cincinnati, OH, (1972) and is a Doctor of Philosophy in Microbiology from the University of Cincinnati, OH, 1979.

Professor Cohen was a research fellow in cancer immunology for the Virginia Commonwealth University Medical College of Virginia in Microbiology/Immunology from 1979 through February, 1982.

Currently a Professor of Microbiology, Immunology and Molecular Genetics at the College of Medicine, University of Kentucky, USA. He also holds a joint appointment at the Graduate Centre for Toxicology, is Scientific Director of the Flo Cytometry Facility, and is a member of the Lucille Parker Markey Cancer Centre at the University of Kentucky.

Professor Cohen is a member of the Professional Association of Immunologists, a member of the Society for Leucocyte Biology and a member of the International Cytokine Society. He is often invited to sit on peak industry bodies and committees and is a published author for the Journal of Leukocyte Biology, the Journal of Immunology, the Journal of Clinical Investigation, the Journal of Endocrinology and the American Journal of Pathology.

By invitation he has presented medical research papers at over 20 conferences, both in the USA and around the world on topics as diverse as HIV, T Cell Activation, Immunology and treatment of Melanoma.

Roger Frantz


Roger Frantz is a proud Alumnus of Bellarmine University where he received his BA in Accounting in 1990. Since receiving his CPA license in 1993, Mr. Frantz has been a long-standing member of the Kentucky Society of CPAs.

In 1995, Mr. Frantz established his company, Roger A Frantz PSC, and began a successful career as a CPA. In his 22 years of experience, Mr. Frantz has worked for a number of high-end clients, including multi-million dollar sales companies and a multi-million dollar restaurant group. He has also performed controller work on numerous manufacturing, construction, restaurant and service industries. In January of 2013, Mr. Frantz began working with Delk Enterprises where he is a valued and respected contributor.